Red Deer, I used 150 mg twice daily with breakfast and supper for six months. After the first few weeks, I felt more confident keeping up with ordinary walking and stayed satisfied with the treatment plan.
Nintedanib, the active substance in Ofev, blocks signals that drive abnormal scar formation in the lungs. Ofev capsules are used under specialist care for idiopathic pulmonary fibrosis and other progressive fibrosing interstitial lung diseases. Treatment aims to slow loss of lung function rather than reverse established fibrosis.
Overview
Ofev is an oral soft-gelatin capsule containing nintedanib esilate. Nintedanib belongs to the tyrosine kinase inhibitor class and is used as an anti-fibrosis treatment for selected progressive lung diseases.
Dosage and administration
Ofev is an oral soft-gelatin capsule available in different strengths. The selected strength depends on the indication, tolerability, liver function, adverse effects, and the prescriber’s treatment plan.
Capsule Strength Selection
For adults receiving treatment for pulmonary fibrosis, the regimen and frequency depend on the purpose of use and are agreed with the treating doctor or pharmacist. A prescriber may select a lower-strength regimen when adverse effects, liver-function changes, or other clinical concerns make the initial regimen unsuitable.
The total amount used each day depends on the indication and the prescriber’s instructions. The prescribed regimen may differ for oncology treatment or when treatment is interrupted and restarted.
Soft-Gelatin Capsule Handling
Ofev capsules should be swallowed whole with liquid. They should not be opened, crushed, chewed, or mixed into food unless a pharmacist has provided specific instructions for an exceptional clinical situation.
The capsule shell is part of the dosage form. Opening it can make administration inaccurate and may expose the mouth or skin to the contents.
Ofev Dosage and Administration
The regimen and frequency for Ofev depend on the indication and are agreed with the treating doctor or pharmacist. Each dose is generally separated according to the prescribed schedule. The Canadian product monograph determines the indication-specific regimen.
- Swallow the capsule whole.
- Take it with food.
- Use the prescribed strength and frequency.
- Do not double the next dose after a missed dose.
- A lower-strength regimen may be used when the prescriber has reduced treatment because of tolerability or clinical factors.
- Keep taking the medicine only according to the current prescription.
Standard Pulmonary-Fibrosis Regimen
Ofev capsules may be prescribed according to a regular schedule for adults with eligible pulmonary fibrosing disease. The treating doctor or pharmacist determines how much to use and how often.
The same schedule should not be automatically applied to a person receiving Ofev for cancer treatment. Oncology dosing follows the indication-specific prescription and may be used with docetaxel.
Dose Reduction and Missed Doses
If a dose is missed, the patient should follow the missed-dose instructions in the Canadian product monograph or the direct plan provided by the prescribing team. Taking two capsules together to compensate is unsafe.
A dose may need to be paused, reduced, or restarted after diarrhoea, liver-enzyme elevation, bleeding, surgery, or another clinically significant problem. These decisions belong to the prescriber.
Formulation
Ofev contains nintedanib, supplied as nintedanib esilate. Nintedanib is the pharmacologically active substance responsible for the anti-fibrotic effect.
Nintedanib Composition
The active pharmaceutical ingredient is nintedanib esilate in a soft-gelatin oral capsule. Ofev is available in 100 mg and 150 mg strengths.
Inactive ingredients can differ between manufacturers. A known allergy or previous reaction to a capsule ingredient should be discussed during the medication review.
Generic Substitution in Canada
A pharmacist can confirm whether a specific nintedanib product is authorized and interchangeable under the applicable provincial rules. Substitution is not determined solely by the active ingredient name; strength, dosage form, authorization, and provincial policy also matter.
How it affects the body
Nintedanib is supplied as nintedanib esilate. It belongs to the tyrosine kinase inhibitor class. These medicines block intracellular signals used by certain growth factors.
In Ofev treatment, this action reduces signalling associated with fibroblast activity, abnormal tissue remodelling, and scar formation. The goal is to slow disease progression. It does not remove established scar tissue or guarantee improved breathing.
Therapeutic indications
Ofev may be prescribed for:
- Idiopathic pulmonary fibrosis.
- Chronic fibrosing interstitial lung diseases with progressive disease behaviour.
- Systemic sclerosis-associated interstitial lung disease.
- Selected oncology indications in jurisdictions where the approved product information includes locally advanced, metastatic, or locally recurrent non-small cell lung cancer in combination with docetaxel.
Oncology use is indication-specific and may differ between countries. Canadian patients should follow the current Health Canada product monograph and the plan provided by their oncologist. The pulmonary regimen and oncology regimen should not be treated as interchangeable.
Common mistakes
Administration Mistakes to Avoid
- Taking the capsule on an empty stomach when the prescription specifies food.
- Opening or chewing the soft-gelatin capsule.
- Taking two doses together after forgetting one.
- Reducing the dose without reporting the problem that caused the change.
- Waiting through persistent diarrhoea until dehydration develops.
- Assuming nausea or poor appetite is unrelated to treatment.
- Starting an over-the-counter medicine or supplement without a medication review.
- Missing liver-function appointments.
When not to use it
Ofev may not be for you if you have a relevant contraindication, moderate-to-severe hepatic impairment, or cannot follow the required monitoring plan.
Moderate-to-severe hepatic impairment is generally unsuitable for Ofev. Ofev is generally not recommended in moderate-to-severe hepatic impairment, classified as Child-Pugh B or C, according to product information [1].
Nintedanib may increase bleeding concerns, especially in people using anticoagulants or antiplatelet medicines. It also requires caution in people with cardiovascular disease, known aneurysm risk, recent major surgery, or conditions associated with gastrointestinal perforation.
When this is not for you
Ofev is not suitable for everyone.
Before the first dose, the prescriber needs a clear history of liver disease, bleeding problems, cardiovascular disease, gastrointestinal disease, planned surgery, pregnancy, breastfeeding, and all medicines or supplements.
Nintedanib may harm an unborn baby. Pregnancy plans, possible pregnancy, and breastfeeding must be discussed before treatment begins.
Tell the treatment team about planned surgery or a recent operation. Nintedanib may affect wound healing and bleeding risk, so timing around a procedure may require a temporary interruption.
Do not stop anticoagulants or antiplatelet medicines without a specific clinical plan.
Possible side effects
Diarrhoea is the side effect patients most often need to manage actively. Nausea, vomiting, reduced appetite, weight loss, abdominal discomfort, and elevated liver enzymes can also occur. The Canadian monograph provides the definitive frequency categories and management instructions for Ofev.
Common Gastrointestinal Effects
Diarrhoea may become clinically significant when it is frequent, watery, persistent, or accompanied by dizziness, weakness, dry mouth, or reduced urination. Fluid loss can lead to dehydration and may require treatment interruption.
Food, adequate fluid intake, and early communication with the care team can help. Anti-diarrhoeal treatment may be appropriate for some patients, but the choice depends on the patient’s clinical picture.
Nausea and reduced appetite can affect nutrition. A symptom diary that records meals, bowel movements, vomiting, weight changes, and capsule times gives the clinician more useful information than a general statement that the medicine “does not agree.”
Liver Injury and Laboratory Monitoring
Nintedanib can increase liver enzymes and, rarely, cause clinically significant drug-induced liver injury. Liver-function tests are checked before treatment and during treatment according to the prescriber’s monitoring plan.
Abnormal results may lead to closer testing, a temporary interruption, or a lower dose. Mild hepatic impairment, classified as Child-Pugh A, may require dose adjustment.
Symptoms that need prompt medical assessment include yellowing of the skin or eyes, dark urine, unusually pale stools, severe tiredness, persistent right-upper-abdominal pain, or unexplained widespread itching.
Serious Bleeding, Cardiovascular, and Gastrointestinal Risks
Seek urgent medical care for:
- Chest pain, fainting, or severe shortness of breath.
- Sudden weakness, facial drooping, confusion, or difficulty speaking.
- Black stools, vomiting blood, or uncontrolled bleeding.
- Severe or rapidly worsening abdominal pain.
- A serious allergic reaction with swelling or breathing difficulty.
These symptoms should not be managed by simply skipping the next capsule.
Comparison
Ofev and pirfenidone are different anti-fibrotic options used in the management of idiopathic pulmonary fibrosis. Neither is automatically preferable for every patient.
| Treatment | Main clinical considerations |
|---|---|
| Ofev — nintedanib | Usually twice daily with food; diarrhoea and liver-enzyme changes require attention |
| Pirfenidone | Multiple daily doses; nausea, appetite changes, photosensitivity, and liver monitoring may influence selection |
Clinicians consider lung-function trajectory, liver health, gastrointestinal tolerance, sun sensitivity, other medicines, adherence, and patient priorities. Combination treatment is not routine for every person and should not be started independently.
A patient who struggles with diarrhoea on Ofev may need supportive treatment, a temporary interruption, or a dose reduction. A patient who struggles with another anti-fibrotic may have a different set of tolerability concerns. The choice is a clinical trade-off, not a universal ranking.
What doctors say
In respiratory practice, Ofev is usually discussed as a disease-slowing treatment. The aim is to preserve lung function for longer, not to promise that existing fibrosis will disappear.
A specialist also weighs treatment burden. Twice-daily capsules, diarrhoea management, liver tests, weight changes, bleeding risk, and other chronic medicines all affect whether the regimen remains sustainable.
One practical clinical observation is that a patient may stop treatment too early after a manageable gastrointestinal symptom. Another may tolerate symptoms silently until dehydration or weight loss becomes serious. Early reporting gives the team more options, including dietary measures, supportive treatment, temporary interruption, or dose reduction. Regular follow-up helps assess whether those measures are working. Decisions should reflect symptoms, test results, and the patient’s treatment goals.
Common questions
Can people under 18 use Ofev?
Ofev is generally used in adults, and paediatric treatment requires an indication-specific specialist decision. Health Canada’s 2023 product information should guide any exceptional use in a person under 18. A child or adolescent should not receive an adult capsule regimen without a paediatric respiratory team’s direction.
What should I do after a missed dose?
Do not take two Ofev doses together to replace a missed dose. Follow the missed-dose instructions in the Canadian monograph or the specific plan provided by the prescribing team. Health Canada’s 2023 product information should take priority over general internet advice because the correct action can depend on how close the missed dose is to the next scheduled dose.
Should Ofev be taken with food or on an empty stomach?
Ofev should be taken with food. Food may improve gastrointestinal tolerability, which matters because diarrhoea, nausea, vomiting, and appetite loss can affect continued treatment. Health Canada’s 2023 Canadian product monograph remains the controlling reference for administration instructions and dose management.
Do you offer anonymous delivery?
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
Customer Feedback on Ofev
Oshawa, I took Ofev 150 mg twice daily for six months, and it fitted into my morning and evening routine better than I expected. I noticed a clearer sense of stability during daily activities and was pleased with the benefit over the following months.
Moncton, I took Ofev 150 mg twice daily for three months. It helped slow the decline I was noticing, but diarrhoea became inconvenient during the first part of treatment. My doctor adjusted the plan, and the benefit was worth continuing after that change.
St. John's, I took Ofev 150 mg twice daily with meals for five months, which made the routine straightforward. I felt that ordinary tasks required less effort after several weeks and was satisfied with the treatment result.
Saint John, I took Ofev 150 mg twice daily for two months. I did not notice much improvement at first, and nausea made some meals difficult. I spoke with my doctor, who reviewed the dose and monitoring plan before I decided whether to continue.
Sources
- European Medicines Agency (2025). Ofev: EPAR — Risk Management Plan